The aim of the current study was to compare everolimus-eluting stents (EES) with sirolimus-eluting stents (SES) in patients undergoing primary angioplasty.
. Even though stent implantation, compared with balloon angioplasty, has reduced the occurrence of restenosis in selected STEMI patients (3, 4) , the outcome of bare-metal stents (BMS) seem to be worse in unselected patients with a rate of target vessel revascularization (TVR) up to 20% (5, 6) . Several randomized trials have shown that drug-eluting stents (DES), compared with BMS, are associated with a significant reduction in restenosis and TVR in STEMI patients (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . However, concerns have emerged on the higher risk of stent thrombosis (ST) with first-generation DES (18) .
The new-generation DES with more biocompatible polymers may potentially provide benefits in both TVR and ST in the setting of STEMI (19) . Therefore, Open-label randomization was performed in the catheterization laboratory after initial angiography by the treating physician when eligibility criteria were met. A 1:1 computer-generated random sequence, without blocking or stratification, was used. Sealed envelopes indicated the treatment group to which the patients were assigned: SES or EES.
MEDICATIONS. All patients received a 70 U/kg intravenous bolus of unfractionated heparin, aspirin intravenously (500 mg), and clopidogrel (600-mg loading dose). Glycoprotein IIb/IIIa inhibitor administration, and the number and length of stents to be implanted were left to the operator's discretion. Postinterventional antiplatelet therapy for all patients consisted of aspirin (100 mg/day) indefinitely and clopidogrel (75 mg daily recommended for 12 months).
ANGIOPLASTY PROCEDURE. Stenting procedures were performed according to standard techniques.
The number and length of stents to be implanted were ACE ¼ angiotensin-converting enzyme; other abbreviations as in Table 1 .
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FIGURE 1 MACE in SES Versus EES
Kaplan-Meier curves showing the occurrence of major adverse cardiac events (MACE) in sirolimus-eluting stents (SES) versus everolimus-eluting stents (EES). Table 3) .
CLINICAL OUTCOME AT FOLLOW-UP. Follow-up data were available in all patients (1,095 AE 159 days).
No difference was observed in terms of duration of dual antiplatelet therapy between the 2 groups ( Table 3) .
FIGURE 3 Reinfarction in SES Versus EES
Kaplan-Meier curves showing the occurrence of reinfarction in SES versus EES.
Abbreviations as in Figure 1 . 
Di Lorenzo et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 7 , N O . 8 , 2 0 1 4 EES vs. SES in Primary Angioplasty
A U G U S T 2 0 1 4 : 8 4 9 Table 4 . Landmark analysis showed benefits with EES within and later than 1-year follow-up as compared to benefits associated with SES (Fig. 5) .
S t e n t t h r o m b o s i s . ST was observed in 17 patients
Target-vessel revascularization. TVR was observed in 24 patients (4.8%). As reported in Figure 6 , no dif- Table 1 . 
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A U G U S T 2 0 1 4 : 8 4 9 -5 6 trial, 625 patients with acute MI were randomized STUDY LIMITATIONS. Despite long-term follow-up data, due to the relatively small sample size, the study is underpowered to evaluate mortality and other secondary endpoints. Furthermore, a larger use of thrombectomy devices, by reducing the thrombotic burden, might have potentially affected the results of our study (25) .
CONCLUSIONS
This study shows that among STEMI patients undergoing primary angioplasty, at 3-year follow-up EES and SES are equally effective, whereas EES is associated with a significant reduction in definite/probable ST. Therefore, while waiting for the results of additional large studies with long-term follow-up data, EES may be safely considered for use in STEMI patients undergoing primary angioplasty.
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